PT  - JOURNAL ARTICLE
AU  - Baratto, Lucia
AU  - Song, Hong
AU  - Duan, Heying
AU  - Hatami, Negin
AU  - Bagshaw, Hilary P.
AU  - Buyyounouski, Mark
AU  - Hancock, Steven
AU  - Shah, Sumit
AU  - Srinivas, Sandy
AU  - Swift, Patrick
AU  - Moradi, Farshad
AU  - Davidzon, Guido
AU  - Iagaru, Andrei
TI  - PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
AID  - 10.2967/jnumed.120.259630
DP  - 2021 Nov 01
TA  - Journal of Nuclear Medicine
PG  - 1545--1549
VI  - 62
IP  - 11
4099  - http://jnm.snmjournals.org/content/62/11/1545.short
4100  - http://jnm.snmjournals.org/content/62/11/1545.full
SO  - J Nucl Med2021 Nov 01; 62
AB  - Novel radiopharmaceuticals for PET are being evaluated for the diagnosis of biochemical recurrence (BCR) of prostate cancer (PC). We compared the gastrin-releasing peptide receptor–targeting 68Ga-RM2 with the prostate-specific membrane antigen (PSMA)–targeting 68Ga-PSMA11 and 18F-DCFPyL. Methods: Fifty patients underwent both 68Ga-RM2 PET/MRI and 68Ga-PSMA11 (n = 23) or 18F-DCFPyL (n = 27) PET/CT at an interval ranging from 1 to 60 d (mean ± SD, 15.8 ± 17.7 d). SUVmax was collected for all lesions. Results: 68Ga-RM2 PET was positive in 35 and negative in 15 of the 50 patients. 68Ga-PSMA11/18F-DCFPyL PET was positive in 37 and negative in 13 of the 50 patients. Both scans detected 70 lesions in 32 patients. Forty-three lesions in 18 patients were identified on only 1 scan: 68Ga-RM2 detected 7 more lesions in 4 patients, whereas 68Ga-PSMA11/18F-DCFPyL detected 36 more lesions in 13 patients. Conclusion: 68Ga-RM2 remains a valuable radiopharmaceutical even when compared with the more widely used 68Ga-PSMA11/18F-DCFPyL in the evaluation of BCR of PC. Larger studies are needed to verify that identifying patients for whom these 2 classes of radiopharmaceuticals are complementary may ultimately allow for personalized medicine.